PATH | VRL
Menu

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections Among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years After a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda

This article, published in PLoS ONE, reports the results of a study that analyzed the prevalence of vaccine and non-vaccine types of human papillomavirus (HPV) infections among bivalent HPV vaccinated and non-vaccinated women aged 15 to 24 years in Uganda. The authors found significantly lower prevalence of vaccine-type HPV-16/18 strains among vaccinated women when compared with unvaccinated women. They also found that other sexually transmitted infections, such as HIV and syphilis, are an important risk factor for HPV infections of both vaccine and non-vaccine types. The findings concur with existing literature on the effectiveness of bivalent HPV-16/18 vaccine and reinforce the recommendation to vaccinate young girls in adolescence and to integrate other sexual health services into HPV vaccination programs.

Author: Kumakech E, Berggren V, Wabinga H, et al.

Published: 2016

» Visit web page (English)

(Located at journals.plos.org)

Citation: Kumakech E, Berggren V, Wabinga H, et al. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections Among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years After a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda. PLoS ONE. 2016;11(8):e0160099. 

Resource types: Peer-reviewed journal

Diseases/vaccines: Human papillomavirus (HPV)

Topics: Disease burden and surveillance, Vaccine safety and performance, Disease/vaccine specific information

Regions: Africa